



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

14 Sep 2020 (#41)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

- **[NOT-OD-20-164](#): Policy for Charging Personal Protective Equipment to NIH Grants and Cooperative Agreements as Direct Costs.** This guidance applies to all applicants and recipients of NIH grants conducting clinical trials (CT) and clinical research (CR) as defined in the NIH Grants Policy Statement (GPS) [section 1.2](#).
- **[NOT-AI-20-071](#): Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design.** The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals. Research supported under this NOSI should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination are sought. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.
- **[NOT-HL-20-737](#): Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases (HLBS).** This Notice of Special Interest (NOSI) encourages research grant applications focused on palliative care in patients with HLBS diseases across the lifespan. Collaboration between HLBS and palliative care researchers is encouraged. Palliative care research studies, including ancillary studies to ongoing clinical research studies, are encouraged.
- **[NOT-NS-20-005](#): Notice of Special Interest (NOSI): Research in the Emergency Setting.** The purpose of this Notice is to announce an interest in research addressing patients with emergency medical conditions, including trauma. This notice invites basic, translational and clinical research and career development programs that effect all areas of emergency medical care, including injury and trauma. Wherever appropriate, investigators are encouraged to utilize existing research networks, such as the NCATS supported CTSAs, NHLBI-NINDS supported SIREN emergency care research network, the NCI CONCERN oncology emergency research network, or the HRSA supported PECARN paediatric critical care network.

Upcoming Deadlines

- **[Harnessing Data Science for Health Discovery and Innovation in Africa \(DS-I Africa\)](#):**
Research Training Program due date: 24 November 2020
Ethical, Legal, and Social Implications Research due date: 1 December 2020
Open Data Science Platform and Coordinating Center due date: 3 December 2020

Research Hubs non-AIDS application due date: 8 December 2020

Research Hubs AIDS application due date: 8 February 2021

- [Mobile Health: Technology and Outcomes in LMICs](#) AIDS deadline 3 December 2020
- [Emerging Global Leader Award](#) 4 November 2020
- [Global Brain Disorders Research](#) 6 November 2020
- [Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs](#) 12 November 2020
- [Chronic, Noncommunicable Diseases and Disorders Research Training \(NCD-Lifespan\)](#) D43 13 November 2020
- [Ecology and Evolution of Infectious Diseases Initiative \(EEID\)](#) 18 November 2020
- [Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries D43](#) 24 June 2021

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunities

1. Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-299](#)

Type: R21

Reissue of [PAR-18-214](#)

Application Due Date: December 10, 2020, April 9, 2021, August 10, 2021, December 10, 2021, April 11, 2022, August 10, 2022, December 9, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics. Accepting applications that either propose or do not propose clinical trial(s)

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year.

2. Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-300](#)

Type: R01

Application Due Date: December 10, 2020, April 9, 2021, August 10, 2021, December 10, 2021, April 11, 2022, August 10, 2022, December 9, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics. Accepting applications that either propose or do not propose clinical trial(s)

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105